MetLife Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.58M	Sell	7,800 -387	-5%	-$132K	0.01%	926
2025 Q4	$3.26M	Buy	8,187 +195	+2%	+$86.3K	0.02%	825
2025 Q3	$3.64M	Buy	7,992 +231	+3%	+$94.1K	0.02%	783
2025 Q2	$2.53M	Buy	7,761 +466	+6%	+$129K	0.01%	883
2025 Q1	$1.97M	Sell	7,295 -9	-0.1%	-$2.31K	0.01%	1044
2024 Q4	$1.72M	Sell	7,304 -14	-0.2%	-$3.68K	0.01%	1122
2024 Q3	$2.01M	Sell	7,318 -144	-2%	-$37.5K	0.01%	1016
2024 Q2	$1.81M	Buy	7,462 +856	+13%	+$135K	0.01%	1017
2024 Q1	$987K	Buy	6,606 +102	+2%	+$17K	0.01%	1308
2023 Q4	$1.24M	Sell	6,504 -92	-1%	-$15.7K	0.01%	1185
2023 Q3	$1.17M	Buy	6,596 +4	+0.1%	+$763	0.01%	1155
2023 Q2	$1.25M	Sell	6,592 -858	-12%	-$170K	0.01%	1142
2023 Q1	$1.49M	Buy	7,450 +18	+0.2%	+$3.78K	0.01%	1023
2022 Q4	$1.77M	Sell	7,432 -58	-0.8%	-$12.4K	0.01%	955
2022 Q3	$1.5M	Buy	7,490 +5	+0.1%	+$954	0.01%	1000
2022 Q2	$1.09M	Sell	7,485 -278	-4%	-$39.4K	0.01%	1166
2022 Q1	$1.27M	Buy	+7,763	New	+$1.18M	0.01%	1191
2019 Q2	–	Sell	-129	Closed	-$12.1K	–	2432
2019 Q1	$12.1K	Buy	129 +7	+6%	+$585	﹤0.01%	2375
2018 Q4	$8.89K	Sell	122 -1	-0.8%	-$77	﹤0.01%	2389
2018 Q3	$10.8K	Buy	+123	New	+$12.4K	﹤0.01%	2431